MacroGenics (MGNX) Projected to Post Earnings on Tuesday

Key Points

• MacroGenics is set to release its Q2 2025 earnings results on August 5th, with expectations of reporting a loss of ($0.59) per share and revenue of $28.06 million.
• The company's latest earnings report showed a loss of ($0.65) EPS, missing estimates, but revenue was higher than expected at $13.19 million.
• Analysts maintain a consensus rating of "Hold" for MacroGenics with a price target average of $5.71, reflecting recent adjustments from various equity research firms.

MacroGenics (NASDAQ:MGNX - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect MacroGenics to post earnings of ($0.59) per share and revenue of $28.06 million for the quarter.

MacroGenics (NASDAQ:MGNX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.04). MacroGenics had a negative return on equity of 59.84% and a negative net margin of 36.23%. The company had revenue of $13.19 million for the quarter, compared to analysts' expectations of $9.59 million. On average, analysts expect MacroGenics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MacroGenics Stock Performance

Shares of MacroGenics stock opened at $1.67 on Tuesday. MacroGenics has a one year low of $0.99 and a one year high of $5.67. The company has a market cap of $105.36 million, a price-to-earnings ratio of -1.88 and a beta of 1.59. The business's 50 day moving average price is $1.49 and its 200 day moving average price is $1.88.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on MGNX shares. Barclays reiterated an "overweight" rating and issued a $3.00 price objective (down previously from $8.00) on shares of MacroGenics in a report on Wednesday, May 14th. Stifel Nicolaus lowered their target price on MacroGenics from $6.00 to $5.00 and set a "hold" rating for the company in a research note on Wednesday, May 14th. Wall Street Zen raised MacroGenics from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. Finally, B. Riley lowered their target price on MacroGenics from $5.00 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, May 20th. Eight research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $5.71.

Institutional Trading of MacroGenics

Institutional investors and hedge funds have recently made changes to their positions in the company. Amundi purchased a new stake in shares of MacroGenics in the 1st quarter valued at about $272,000. Jones Financial Companies Lllp raised its stake in MacroGenics by 456,243.3% during the 1st quarter. Jones Financial Companies Lllp now owns 136,903 shares of the biopharmaceutical company's stock valued at $174,000 after acquiring an additional 136,873 shares during the last quarter. Finally, Invesco Ltd. raised its stake in MacroGenics by 90.0% during the 1st quarter. Invesco Ltd. now owns 68,377 shares of the biopharmaceutical company's stock valued at $87,000 after acquiring an additional 32,398 shares during the last quarter. 96.89% of the stock is owned by hedge funds and other institutional investors.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.